Probiotics and digestive disease

Nutrition in Clinical Practice

Volumn 27, Issue 2, 2012, Pages 300-302

  Mullin, Gerard E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROBIOTIC AGENT; VSL3;

ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CROHN DISEASE; GASTROINTESTINAL DISEASE; HUMAN; ILEITIS; IRRITABLE COLON; LACTOBACILLUS; NONHUMAN; PRACTICE GUIDELINE; TRAVELLER DIARRHEA; TREATMENT OUTCOME; ULCERATIVE COLITIS; WORLD HEALTH ORGANIZATION;

BACTERIA; DIARRHEA; GASTROINTESTINAL DISEASES; HUMANS; INFECTION; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; PROBIOTICS;

EID: 84859314328     PISSN: 08845336     EISSN: 19412452     Source Type: Journal    
DOI: 10.1177/0884533612439609     Document Type: Article

References (28)

1. Fuller R. Probiotics in man and animals. J Appl Bacteriol. 1989 ; 66 (5). 365-378
2. Quigley EM. Bacterial flora in irritable bowel syndrome: role in pathophysiology, implications for management. J Dig Dis. 2007 ; 8 (1). 2-7
3. Quigley EM, Bytzer P, Jones R, Mearin F. Irritable bowel syndrome: the burden and unmet needs in Europe. Dig Liver Dis. 2006 ; 38 (10). 717-723
4. Quigley EM, Flourie B. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil. 2007 ; 19 (3). 166-172
5. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005 ; 128 (3). 541-551
6. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol. 2006 ; 101 (7). 1581-1590
7. Gawronska A, Dziechciarz P, Horvath A, Szajewska H. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther. 2007 ; 25 (2). 177-184
8. Kajander K, Hatakka K, Poussa T, Farkkila M, Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther. 2005 ; 22 (5). 387-394
9. Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci. 2000 ; 45 (7). 1462-1464
10. Kim HJ, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil. 2005 ; 17 (5). 687-696
11. Guyonnet D, Chassany O, Ducrotte P, et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther. 2007 ; 26 (3). 475-486
12. Kajander K, Krogius-Kurikka L, Rinttila T, Karjalainen H, Palva A, Korpela R. Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome. Aliment Pharmacol Ther. 2007 ; 26 (3). 463-473
13. Ghoshal UC, Park H, Gwee KA. Bugs and irritable bowel syndrome: the good, the bad and the ugly. J Gastroenterol Hepatol. 2010 ; 25 (2). 244-251
14. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010 ; 59 (3). 325-332
15. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol. 2008 ; 14 (17). 2650-2661
16. McFarland LV. Meta-analysis of probiotics for the prevention of traveler's diarrhea. Travel Med Infect Dis. 2007 ; 5 (2). 97-105
17. Bartlett JG. Clostridium difficile-associated enteric disease. Curr Infect Dis Rep. 2002 ; 4 (6). 477-483
18. Tung JM, Dolovich LR, Lee CH. Prevention of Clostridium difficile infection with Saccharomyces boulardii: a systematic review. Can J Gastroenterol. 2009 ; 23 (12). 817-821
19. Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev. 2008 ; ( 1 ):
20. Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol. 2005 ; 100 (7). 1539-1546
21. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009 ; 104 (2). 437-443
22. Sood A, Midha V, Makharia GK, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2009 ; 7 (11). 1202 1209.e1-1209
23. Tursi A. Balsalazide plus high-potency probiotic preparation (VSL#3) in the treatment of acute mild-to-moderate ulcerative colitis and uncomplicated diverticulitis of the colon. J Clin Gastroenterol. 2008 ; 42 (suppl 3, pt 1). S119 - S122
24. Sang LX, Chang B, Zhang WL, Wu XM, Li XH, Jiang M. Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis. World J Gastroenterol. 2010 ; 16 (15). 1908-1915
25. McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 2010 ; 16 (18). 2202-2222
26. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000 ; 119 (2). 305-309
27. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004 ; 53 (1). 108-114
28. Elahi B, Nikfar S, Derakhshani S, Vafaie M, Abdollahi M. On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials. Dig Dis Sci. 2008 ; 53 (5). 1278-1284